Earnings-backed filing view
BOSTON SCIENTIFIC CORP (BSX)
See the latest BSX earnings framing tied back to the filing, including recent revenue and EPS trend context.
Filing summary
BOSTON SCIENTIFIC CORP earnings insights
The filing reads constructive based on revenue and statement momentum.
The latest 10-K for BSX shows revenue was $20.1B.
Informational only, not investment advice. Verify material conclusions in the official filing before acting on any summary.
Key changes
What changed and why it matters
- Revenue moved to $20.1B from $16.7B (+19.9% vs prior).
- Diluted EPS moved to $1.94 from $1.25 (+55.2% vs prior).
- Cash & equivalents moved to $2.0B from $1.3B (+54.1% vs prior).
What matters now
Positive read
Research note
Research note
This company page should work as a first research note, not just a label applied to a filing. The goal is to explain what changed, why that change matters, and which parts of the source filing deserve a slower read.
Use the latest filing summary with the comparison blocks and statement sections. The important question is whether the quarter or year changed the underlying business read, not whether one headline metric looked better than expected.
A good next step is to verify the management framing in the primary source and keep a short watchlist of the two or three metrics most likely to matter in the next report.
What to watch
Company-specific checkpoints for the next filing
- Revenue quality and the main profit driver
- Margin durability
- Cash generation and liquidity
- One company-specific operational risk worth monitoring
Company context
Why BSX stays in the tracked universe
BOSTON SCIENTIFIC CORP is tracked in Quantfil because it sits inside Healthcare / Medical Devices and regularly produces filings that matter to cross-sector read-throughs. The latest 10-K is being used as the current anchor report, while the next earnings date is not currently scheduled in the tracked calendar feed. BOSTON SCIENTIFIC CORP filing dashboard built from SEC EDGAR company facts and recent periodic filings.
This page ties the latest reported quarter for BOSTON SCIENTIFIC CORP back to the filing context. It should help a reader decide whether the quarter improved the operating read or only changed the headline narrative. Most key statement lines improved versus the prior comparable period.
Verification notes
What to focus on next
- Confirm the 10-K filing date, report period, and SEC source link before comparing figures.
- Check whether revenue, EPS, and operating cash flow move together before trusting the quarter's headline.
- Use the current-versus-prior section to decide whether the latest report truly changed the read.
- Read the official 10-K source if a risk-factor change or accounting note could alter the conclusion.
- Use the earnings page to frame the quarter, then confirm the read with the filing-linked company page.
Common mistake
Do not treat the earnings headline or management commentary as complete on its own. Use the filing to confirm whether cash flow, working-capital movement, and footnote detail support the headline story.
Quantfil pages are built from pre-generated public-company data and daily refreshed static assets. They are designed to accelerate the first read, not replace the underlying filing. Next earnings timing is not currently available for this symbol in the tracked public calendar feed.
Financial snapshot
Latest reported figures
Trend section
Recent revenue trend
Current versus prior
How the latest report differs from the previous filing
Current $20.1B · Prior $16.7B
Current $1.94 · Prior $1.25
Current $2.0B · Prior $1.3B
Current $24.2B · Prior $23.4B
Current $4.5B · Prior $3.4B
Related links
Move through the research workflow
Related reading